154 related articles for article (PubMed ID: 29733658)
1. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
Yudistiro R; Hanaoka H; Katsumata N; Yamaguchi A; Tsushima Y
Mol Pharm; 2018 Jun; 15(6):2165-2173. PubMed ID: 29733658
[TBL] [Abstract][Full Text] [Related]
2. Potential of three-step pretargeting radioimmunotherapy using biotinylated bevacizumab and succinylated streptavidin in triple-negative breast cancer xenograft.
Gu W; Yudistiro R; Hanaoka H; Katsumata N; Tsushima Y
Ann Nucl Med; 2021 Apr; 35(4):514-522. PubMed ID: 33582981
[TBL] [Abstract][Full Text] [Related]
3. Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma.
Li GP; Wang YX; Huang K; Zhang H; Zhang CF
World J Gastroenterol; 2005 Apr; 11(13):1917-21. PubMed ID: 15800980
[TBL] [Abstract][Full Text] [Related]
4. Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice.
Sato N; Saga T; Sakahara H; Nakamoto Y; Zhao S; Kuroki M; Iida Y; Endo K; Konishi J
Jpn J Cancer Res; 2000 Jun; 91(6):622-8. PubMed ID: 10874215
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
6. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Mirallié E; Saï-Maurel C; Faivre-Chauvet A; Regenet N; Chang CH; Goldenberg DM; Chatal JF; Barbet J; Thedrez P
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):901-9. PubMed ID: 15864584
[TBL] [Abstract][Full Text] [Related]
7. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.
Li GP; Zhang H; Zhu CM; Zhang J; Jiang XF
World J Gastroenterol; 2005 Oct; 11(40):6288-94. PubMed ID: 16419157
[TBL] [Abstract][Full Text] [Related]
8. Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity.
Kobayashi H; Sakahara H; Endo K; Yao ZS; Toyama S; Konishi J
Eur J Cancer; 1995 Sep; 31A(10):1689-96. PubMed ID: 7488426
[TBL] [Abstract][Full Text] [Related]
9. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
[TBL] [Abstract][Full Text] [Related]
10. Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody.
Hanaoka H; Kuroki M; Yamaguchi A; Achmad A; Iida Y; Higuchi T; Oriuchi N; Tsushima Y; Endo K
Cancer Biother Radiopharm; 2014 Mar; 29(2):70-6. PubMed ID: 24299067
[TBL] [Abstract][Full Text] [Related]
11. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.
Yao Z; Zhang M; Kobayashi H; Sakahara H; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1995 May; 36(5):837-41. PubMed ID: 7738661
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
13. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
14. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
15. In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy.
Yoshioka H; Yamamoto S; Hanaoka H; Iida Y; Paudyal P; Higuchi T; Tominaga H; Oriuchi N; Nakagawa H; Shiba Y; Yoshida K; Osawa R; Katagiri T; Tsunoda T; Nakamura Y; Endo K
Cancer Immunol Immunother; 2012 Aug; 61(8):1211-20. PubMed ID: 22223257
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
Salaun PY; Bodet-Milin C; Frampas E; Oudoux A; Saï-Maurel C; Faivre-Chauvet A; Barbet J; Paris F; Kraeber-Bodéré F
Cancer; 2010 Feb; 116(4 Suppl):1053-8. PubMed ID: 20127950
[TBL] [Abstract][Full Text] [Related]
17. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
18. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96.
Chen JQ; Strand SE; Tennvall J; Lindgren L; Hindorf C; Sjögren HO
J Nucl Med; 1997 Dec; 38(12):1934-9. PubMed ID: 9430473
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy evaluation of radioimmunotherapy with
Sudo H; Tsuji AB; Sugyo A; Saga T; Kaneko MK; Kato Y; Higashi T
Cancer Sci; 2019 May; 110(5):1653-1664. PubMed ID: 30801908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
